

Predictors for nocturnal hypoxaemia (mean $SaO_2 < 90\%$) in normoxic and mildly hypoxic patients with COPD

P.J.E. Vos, H.Th.M. Folgering, C.L.A. van Herwaarden

Predictors for nocturnal hypoxaemia (mean $SaO_2 < 90\%$) in normoxic and mildly hypoxic patients with COPD. P.J.E. Vos, H.Th.M. Folgering, C.L.A. van Herwaarden. ©ERS Journals Ltd 1995.

ABSTRACT: Detection of nocturnal hypoxaemia, defined as a mean arterial oxygen saturation below 90%, in normoxic or mildly hypoxic chronic obstructive pulmonary disease (COPD) patients seems clinically relevant, since this feature may precede pulmonary hypertension. Nocturnal studies are expensive and time-consuming procedures. The current study investigates to what extent it is possible to predict nocturnal hypoxaemia from daytime parameters.

Forty two COPD patients with a daytime arterial oxygen tension (Pao_2) above 8 kPa participated. Nocturnal oxygenation, daytime blood gas values, and ventilatory responses to hypercapnia were measured.

In 10 patients, enough desaturations occurred to qualify as nocturnal hypoxaemia. They had a significantly lower daytime Pao_2 value, and a lower steady-state hypercapnic ventilatory response. They also smoked more often, and complained about daytime sleepiness. Multiple linear regression analysis demonstrated that daytime Pao_2 (32%) was the best independent predictor. Sleepiness (12%), and number of cigarettes smoked (5%) also contributed independently, but in a minor way. Patients with a high daytime Pao_2 (>11 kPa) did not develop nocturnal hypoxaemia.

The hypercapnic ventilatory response was used to distinguish nocturnal hypoxaemic from normoxaemic patients. Only patients with a low response ($< 3.5 \text{ l}\cdot\text{min}^{-1}\cdot\text{kPa}^{-1}$) appeared to run a risk of developing nocturnal hypoxaemia. The sensitivity of this test was 80%, and the specificity 70%.

It is concluded that daytime Pao_2 , hypercapnic ventilatory response and sleepiness are helpful in predicting nocturnal hypoxaemia.

Eur Respir J., 1995, 8, 74–77.

Dept of Pulmonary Diseases, University of Nijmegen, Groesbeek, The Netherlands.

Correspondence: P.J.E. Vos
Dept of Pulmonary Diseases
University of Nijmegen
Medical Centre Dekkerswald
P.O. Box 9001
6560 GB Groesbeek
The Netherlands

Keywords: Chronic obstructive pulmonary disease
hypercapnic ventilatory response
nocturnal hypoxaemia
predictors

Received: November 9 1993
Accepted after revision October 16 1994

This study was supported by a grant from the Dutch Asthma Foundation.

Episodes of oxygen desaturation may occur during sleep in patients with chronic obstructive pulmonary disease (COPD) [1–4]. In severe hypoxaemic COPD patients, such episodes are treated adequately when long-term supplemental oxygen is administered [5–7]. COPD patients with mild daytime hypoxia or normoxia ($Pao_2 > 8$ kPa) may also have transient oxygen desaturations during sleep, but they may not be apparent to physicians who only evaluate daytime blood gas values [8–10]. Nevertheless, this transient nocturnal hypoxaemia is accompanied by elevated pulmonary artery pressures [1–4, 8, 11–17]. Moreover, it has been suggested that these transient elevations of the pulmonary artery pressure may lead to sustained pulmonary hypertension; and, finally, to the development of right heart failure [8, 12, 14, 17–23].

In practice, it is not feasible to perform expensive nocturnal studies in all COPD patients who are mildly hypoxic or normoxic whilst awake. Therefore, it has been investigated whether daytime characteristics predict oxygenation during sleep in these patients. LEVI-VALENSI *et al.* [8] showed a significant relationship between the baseline arterial oxygen saturation (SaO_2) awake and nocturnal SaO_2 , in COPD patients with a Pao_2 awake

above 8 kPa. FLETCHER *et al.* [10] indicated that the desaturators had lower Pao_2 and higher arterial carbon dioxide tension ($Paco_2$) values awake than nondesaturators. Furthermore, BRADLEY *et al.* [9] showed that daytime hypercapnia is a risk factor for the development of nocturnal hypoxaemia in COPD patients with mild daytime hypoxaemia. However, all these parameters have appeared to be of little predictive value [8–10].

The purpose of the current study was to evaluate in COPD patients with mild daytime hypoxaemia or normoxia ($Pao_2 > 8$ kPa), several daytime parameters as possible predictors of nocturnal hypoxaemia. The latter was defined as a mean nocturnal SaO_2 below 90%.

Methods

Patients

Forty two patients with COPD (American Thoracic Society (ATS) criteria [5]) participated in this study. Inclusion criteria were: daytime Pao_2 above 8.0 kPa; and

Table 1. – Characteristics of the COPD patients

	All	Mean Noct. Sao ₂ <90%	Mean Noct. Sao ₂ ≥90%
Sex M/F	39/3	10/0	29/3
Age yrs	67 (7)	66 (6)	68 (7)
FEV ₁ % pred	35 (10)	31 (10)	36 (11)
IVC % pred	80 (17)	71 (17)	82 (17)
TLC % pred	100 (22)	98 (32)	100 (18)
FRC % pred	131 (32)	140 (46)	128 (26)
RV % pred	146 (43)	163 (65)	141 (33)
HCVR l·min ⁻¹ ·kPa ⁻¹	4.2 (4)	2.1 (2)	4.9 (4.2)*
Pao ₂ daytime kPa	9.8 (1.1)	9.1 (0.7)	10.0 (1.1)*
Paco ₂ daytime kPa	5.4 (0.7)	5.8 (0.9)	5.3 (0.6)†
Body mass index	23 (3)	23 (4)	23 (3)
Smoking %	24	50	16†
Sleepiness %	24	60	12*
Mean noct. Sao ₂ %	91 (2.3)	88 (1.8)	92 (1.5)*
Lowest noct. Sao ₂ %	83 (6.7)	78 (5.7)	85 (5.9)*

Data are presented as mean (SD). COPD: chronic obstructive pulmonary disease; Noct.: nocturnal; M: male; F: female; FEV₁: forced expiratory volume in one second; IVC: inspiratory vital capacity; TLC: total lung capacity; FRC: functional residual capacity; RV: residual volume; % pred: percentage of predicted; HCVR: hypercapnic ventilatory response; Pao₂: arterial oxygen tension; Paco₂: arterial carbon dioxide tension; Sao₂: arterial oxygen saturation; body mass index: body weight (kg)/length² (m). *: p < 0.05; †: 0.1 < p < 0.05.

a forced expiratory volume in one second (FEV₁) value less than 65% of predicted [24]. The patient characteristics are shown in table 1. All patients were in a stable clinical condition, and received optimal bronchodilatory therapy. All medication was continued, except for benzodiazepines. Each subject gave informed consent. The study was approved by the Hospital Ethics Committee.

Techniques and protocol

Daytime. Arterial blood gas samples were obtained and pulmonary function parameters were determined. The ventilatory response to CO₂ was measured using the steady-state method [25]. The patient was connected to a closed spirometric circuit by means of a mouthpiece. The end-tidal carbon dioxide tension (PETCO₂) level was increased 1 kPa, by adjusting a three-way valve, partially short-circuiting the CO₂ absorber in the inspiratory limb of the circuit. Each level (baseline, 1 kPa above baseline) was studied over 5 min. The oxygen saturation level was maintained at 97% or more, by adding oxygen to the system.

Table 2. – Correlations between the mean nocturnal Sao₂ and daytime characteristics

	Sao ₂ daytime %	Pao ₂ daytime kPa	HCVR l·min ⁻¹ ·kPa ⁻¹	Cigarettes daily n	Sleepiness
Mean nocturnal Sao ₂	0.56*	0.58*	0.41*	-0.49*	-0.45*

*: p < 0.05. None of the other daytime parameters was significantly correlated. For abbreviations see legend to table 1.

The patients were questioned about the number of cigarettes they smoked daily. Daytime sleepiness was considered to be present when the sleepiness interfered with daily life, or had been noticed by other people.

Night-time. Oxygen saturation (Oxyshuttle, SensorMedics), chest-wall movements (Vitalog), oronasal airflow (thermistors), electromyogram (EMG) of the intercostal muscles, and electro-oculogram (EOG) were recorded from 10 p.m. until 6 a.m. The electromyogram of the 2nd and 3rd parasternal intercostal muscles was recorded with surface electrodes, rectified and integrated. EMG-activity indicated breathing efforts.

The saturation data of the whole night were stored, digitized and analysed by a computer (Apple IIe) to provide the mean and the lowest saturation of each night. Desaturation was defined as a decrease of more than 4% in oxygen saturation from the asleep baseline Sao₂. The asleep baseline Sao₂ was defined as the mean saturation 15 min after falling asleep, lying in a horizontal position. Nocturnal hypoxaemia was defined as a mean Sao₂ below 90%.

Central apnoea was defined as a cessation of airflow, thoracoabdominal movement, and activity of the intercostal muscles for at least 10 s. Obstructive apnoea was defined as absence of airflow for at least 10 s in the presence of thoracoabdominal movement and intercostal muscle activity.

Indication for rapid eye movement (REM) sleep was shown when regular EOG activity was present.

Statistics

Statistical analyses to compare patient characteristics of the two groups were performed using the Wilcoxon two sample test and the Chi-squared test. Relationships between variables were evaluated with Spearman's rank correlation. Furthermore, partial correlations were determined by multiple linear regression analysis.

Results

In 33 of the 42 patients, one or more nocturnal desaturations occurred. In 10 patients, mean nocturnal oxygen saturation was below 90%. These 10 patients had significantly lower daytime Pao₂ values and lower hypercapnic ventilatory responses than the 32 others (table 1). Furthermore, they complained more often about sleepiness. In one patient more than 10 obstructive apnoeas·h⁻¹ were found.

Table 3. – Results of the HCVR as a screening method to distinguish patients with nocturnal hypoxaemia (mean $SaO_2 < 90\%$: positive test) and without nocturnal hypoxaemia (mean $SaO_2 \geq 90\%$: negative test) (patients with a HCVR below $3.5 \text{ l}\cdot\text{min}^{-1}\cdot\text{kPa}^{-1}$ were considered prone to nocturnal hypoxaemia)

	Total n	Predicted mean	
		$SaO_2 < 90\%$	$SaO_2 \geq 90\%$
Real			
mean $SaO_2 < 90\%$	10	8	2
mean $SaO_2 \geq 90\%$	27	8	19
Total	37	16	21

Spearman's rank correlation showed a significant relationship between the mean nocturnal SaO_2 and daytime SaO_2 , daytime PaO_2 , the hypercapnic ventilatory response, and number of cigarettes smoked daily (table 2). Presence of sleepiness also appeared to be significantly different, indicating that sleepy persons had a lower mean nocturnal desaturation (Chi-squared test, $p=0.01$).

The partial correlations to the prediction of the mean nocturnal SaO_2 were determined by multiple linear regression analysis. This showed that daytime PaO_2 (32%), sleepiness (12%), and number of cigarettes smoked (5%), contributed independently to the total variance of 49% of the mean nocturnal SaO_2 . The prediction equation was: mean nocturnal $SaO_2 = 83.3 + 0.89 PaO_2 - 2 \text{ sleepiness} - 0.24 \text{ number of daily cigarettes}$. ($r = a + bx + cy + dz$), in which sleepiness was scored yes=1, or no=0.

No patients with a daytime PaO_2 above 11.0 kPa developed nocturnal hypoxaemia. The large overlap in daytime PaO_2 made it impossible to distinguish between patients with and without nocturnal hypoxaemia.

When the ability of the hypercapnic ventilatory response to separate the nocturnal hypoxaemic and normoxaemic group was examined in the remaining patients with a daytime PaO_2 below 11.0 kPa, a cut-off point for the response of $3.5 \text{ l}\cdot\text{min}^{-1}\cdot\text{kPa}^{-1}$ was calculated to yield the highest sensitivity in the prediction of nocturnal hypoxaemia. The results of the hypercapnic ventilatory response as a screening test are shown in table 3. Two patients were falsely classified as not having nocturnal hypoxaemia. Eight patients were falsely classified as having nocturnal hypoxaemia. The sensitivity of this test was 80%, and the specificity 70%. The negative predictive value was 91%, and the positive predictive value 50%.

Discussion

This study shows that nocturnal hypoxaemia was present in 10 of the 42 patients with normoxia or mild hypoxia. No patient with a PaO_2 above 11.0 kPa developed nocturnal hypoxaemia.

The patients with nocturnal hypoxaemia had a significantly lower PaO_2 value, lower hypercapnic ventilatory response, and more complaints of sleepiness. The large overlap in daytime PaO_2 made it impossible to predict nocturnal hypoxaemia in every individual patient.

However, the hypercapnic ventilatory response appeared to be helpful to indicate nocturnal hypoxaemia; and may, therefore, avoid redundant sleep studies. If sleep studies were performed only in those patients with a hypercapnic ventilatory response below $3.5 \text{ l}\cdot\text{min}^{-1}\cdot\text{kPa}^{-1}$, two of the nocturnal hypoxaemic patients (20%) would be missed, whereas 8 of the nocturnal normoxic patients (22%) would be measured unnecessarily. One of the two patients with unexpected nocturnal hypoxaemia had an obstructive sleep apnoea/hypopnoea syndrome. The negative predictive value of the test as a screening method in the current study was 91%, which is quite reasonable.

Our results are similar to those demonstrated in hypoxic COPD patients [26, 27]. Patients with higher CO_2 responses were not likely to develop nocturnal hypoxaemia, whereas patients with lower ventilatory responses to CO_2 might or might not have nocturnal hypoxaemia. It suggests that a blunted chemical drive by itself does not necessarily cause the nocturnal hypoxaemia, but allows the hypoxaemia, which is caused by other factors, such as ventilation-perfusion mismatching and changes in functional residual capacity [2], to persist. Other parameters, not measured in this study, but possibly influencing the nocturnal saturation are, for instance, respiratory muscle performance. Not only is the functioning of the central nervous respiratory organization important in this respect, but also the properties of the effector organ; *i.e.* the respiratory muscles. It was shown by HEYDRA *et al.* [28] that nocturnal desaturations in COPD patients are also associated with respiratory muscle dysfunction.

The hypercapnic ventilatory response was measured by the steady-state method. In order to restrict the burden on patients due to CO_2 -loading, only two steps of the CO_2 -response curve were measured. A possible drawback of this method may be that it disregards the nonlinearity in the CO_2 -response curve at low $Paco_2$ levels (dog-leg). However, since most patients were normocapnic or hypercapnic, and since the step in $PETCO_2$ was rather high, the effect of the slope can only be of minor importance. Furthermore, a nonlinearity of the CO_2 response curve is most prominent in hypoxic conditions. Since our patients were kept normoxic, a nonlinear CO_2 response curve in normoxic and hypercapnic ranges is unlikely.

Only a small number of patients participated in this study, and the cut-off point for the hypercapnic ventilatory response had a low positive predictive value (50%). The validation of the test still has to be established in a prospective study.

The results of this study have some practical implications. Firstly, nocturnal hypoxaemia in patients with a daytime PaO_2 above 11.0 kPa is very unlikely. Secondly, in COPD patients with a daytime PaO_2 below 11.0 kPa and above 8.0 kPa, measurement of the hypercapnic ventilatory response may be helpful as a screening test. Only in patients with responses below $3.5 \text{ l}\cdot\text{min}^{-1}\cdot\text{kPa}^{-1}$, are nocturnal studies indicated.

Acknowledgement: The authors would like to express their gratitude to Th.M. de Boo and W.A.J.G. Lemmens for statistical assistance.

References

1. Douglas NJ. Nocturnal hypoxemia in patients with chronic obstructive pulmonary disease. *Clin Chest Med* 1992; 13: 523–532.
2. Douglas NJ, Flenley DC. Breathing during sleep in patients with chronic obstructive lung disease: state of the art. *Am Rev Respir Dis* 1990; 141: 1055–1070.
3. Douglas NJ. Are sleep studies necessary in COPD? *Lung* 1990; (Suppl.): 943–947.
4. Catterall JR, Calverley PMA, MacNee W, *et al.* Mechanism of transient nocturnal hypoxemia in hypoxic chronic bronchitis and emphysema. *J Appl Physiol* 1985; 59: 1698–1703.
5. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma: an official statement of the American Thoracic Society. *Am Rev Respir Dis* 1987; 136: 225–243.
6. Weitzenblum E, Sautegau A, Ehrhart M, Mammosser M, Pelletier A. Long-term oxygen therapy can reverse the progression of pulmonary hypertension in patients with chronic obstructive pulmonary disease. *Am Rev Respir Dis* 1985; 131: 493–498.
7. Timms RM, Khaja FU, Williams GW. Hemodynamic response to oxygen therapy in chronic obstructive pulmonary disease. *Ann Intern Med* 1985; 102: 29–36.
8. Levi-Valensi P, Weitzenblum E, Rida Z, *et al.* Sleep-related oxygen desaturation and daytime pulmonary haemodynamics in COPD patients. *Eur Respir J* 1992; 5: 301–307.
9. Bradley TD, Mateika J, Li D, Avendano M, Goldstein RS. Daytime hypercapnia in the development of nocturnal hypoxaemia in COPD. *Chest* 1990; 97: 308–312.
10. Fletcher EC, Miller J, Divine GW, Fletcher JC, Miller T. Nocturnal oxyhemoglobin desaturation in COPD patients with arterial oxygen tensions above 60 mmHg. *Chest* 1987; 92: 604–608.
11. Ressler J, Urbanova D, Widimsky J, Ostadal B, Pelouch V, Prochazka J. Reversibility of pulmonary hypertension and right ventricular hypertrophy induced by intermittent altitude hypoxia in rats. *Respiration* 1974; 31: 38–46.
12. Nattie EE, Bartlett Jr D, Johnson K. Pulmonary hypertension and right ventricular hypertrophy caused by intermittent hypoxia and hypercapnia in the rat. *Am Rev Respir Dis* 1978; 118: 653–658.
13. Coccagna G, Lugaresi E. Arterial blood gases and pulmonary and systemic arterial pressure during sleep in chronic obstructive pulmonary disease. *Sleep* 1978; 1: 117–124.
14. Boysen PG, Block JA, Wynne JW, Hunt LA, Flick MR. Nocturnal pulmonary hypertension in patients with chronic obstructive pulmonary disease. *Chest* 1979; 5: 536–542.
15. Fletcher EC, Levin DC. Cardiopulmonary hemodynamics during sleep in subjects with chronic obstructive pulmonary disease: the effect of short- and long-term oxygen. *Chest* 1984; 85: 6–14.
16. Boysen PG. Nocturnal oxygen therapy and hemodynamic changes in COPD. *Chest* 1984; 85: 2–3.
17. Fletcher EC, Luckett RA, Miller T, Costaragas C, Kutka N, Fletcher JG. Pulmonary vascular hemodynamics in chronic lung disease patients with and without oxyhemoglobin desaturation during sleep. *Chest* 1989; 95: 757–764.
18. Moore-Gillon JC, Cameron IR. Right ventricular hypertrophy and polycythemia in rats after intermittent exposure to hypoxia. *Clin Sci* 1985; 69: 595–599.
19. Midgren B, White T, Petersson K, Bryhn M, Airikkala P, Elmqvist D. Nocturnal hypoxaemia and cor pulmonale in severe chronic lung disease. *Bull Eur Physiopathol Respir* 1985; 21: 527–533.
20. Flenley DC. Clinical hypoxia: causes, consequences and correction. *Lancet* 1978; i: 542–546.
21. Block AJ, Boysen PG, Wynne JW. The origins of cor pulmonale: a hypothesis. *Chest* 1979; 75: 109–110.
22. Block AJ. Dangerous sleep: oxygen therapy for nocturnal hypoxaemia. *N Engl J Med* 1982; 306: 166–167.
23. Reid LM. Structure and function in pulmonary hypertension. *Chest* 1986; 89: 279–288.
24. Quanjer Ph. Standardized lung function testing. *Eur Respir J* 1993; 6 (Suppl.): 16.
25. Smolders F, Folgering H, Bernards J. Capnostat and oxystat: electronic devices to automatically maintain the end-tidal P_{aCO_2} and P_{aO_2} of a subject connected to a closed respiratory circuit at adjustable levels. *Pfluegers Arch* 1977; 372: 289–290.
26. Fleetham JA, Mezon B, West P, Bradley CA, Anthonisen NR, Kryger MH. Chemical control of ventilation and sleep arterial oxygen desaturation in patients with COPD. *Am Rev Respir Dis* 1980; 122: 583–589.
27. Tatsumi K, Kimura H, Kunitomo F, Kuriyama T, Watanabe S, Honda Y. Sleep arterial oxygen desaturation and chemical control of breathing during wakefulness in COPD. *Chest* 1986; 90 (1): 68–73.
28. Heydra Y, Dekhuijzen PNR, van Herwaarden CLA, Folgering HTM. The relationship between nocturnal oxygen desaturations and inspiratory muscle strength in COPD patients. *Eur Respir J*, 1992; 5 (Suppl. 15): 25S–26S.